Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helius THC10:CBD10
- Development stage
- Phase 3
- Lead developer
- Helius Therapeutics
- Modality
- Small Molecules
- Administration
- Sublingual, Oral
01
Overview
Helius THC10:CBD10 Full Spectrum is a New Zealand-produced, full-spectrum cannabis-based oral liquid solution containing a balanced 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), with each phytocannabinoid present at a concentration of 10 mg/mL. Developed and manufactured by Helius Therapeutics, the product is formulated as a plant extract in oil for sublingual administration. It is currently being evaluated in a Phase 3 clinical trial sponsored by the University of Auckland for the treatment of insomnia in adults with chronic back pain. The medication works by interacting with the endocannabinoid system, primarily acting as an agonist at the CB1 and CB2 cannabinoid receptors to modulate pain and sleep pathways.
- Brand names
- Helius THC10:CBD10 Full SpectrumHelius THC10 + CBD10
- Other names
- THC10:CBD10THC10 + CBD10
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Helius THC10:CBD10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helius THC10:CBD10.